Cholera toxin B pretreatment of macrophages and monocytes diminishes their proinflammatory responsiveness to lipopolysaccharide

Journal of Immunology

Volumn 168, Issue 4, 2002, Pages 1730-1737

  Burkart, Volker ^a   Kim, Yoong Eun ^a   Hartmann, Bettina ^a   Ghiea, Iona ^a   Syldath, Ulrike ^a   Kauer, Manfred ^a   Fingberg, Waltraud ^a   Hanifi Moghaddam, Pejman ^a   Müller, Sylvia ^a   Kolb, Hubert ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHOLERA TOXIN B SUBUNIT; ENDOTOXIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DESENSITIZATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0037083339     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.4.1730     Document Type: Article

References (44)

1. Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance
2. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit
3. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes
4. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine
5. Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-β-secreting cells and suppressing chemokine expression
6. Oral administration of collagen conjugated with cholera toxin induces tolerance to type II collagen and suppresses chondritis in an animal model of autoimmune ear disease
7. The B-subunit of cholera toxin induces immunoregulatory cells and prevents diabetes in the NOD mouse
8. Prevention of autoimmune disease due to lymphocyte modulation by the B-subunit of Escherichia coli heat-labile enterotoxin
9. Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: Receptor binding is essential and induces differential modulation of lymphocyte subsets
10. + T lymphocytes
11. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
12. Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: Receptor interaction up-regulates MHC class II, B7, CD40, CD25 and ICAM-1
13. Cyclic AMP-independent effects of cholera toxin on B cell activation. II. Binding of ganglioside GM1 induces B cell activation
14. Prevention of acute graft-versus-host disease by treatment with a novel immunosuppressant: Cholera toxin B subunit
15. + regulatory T-cells
16. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant
17. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes
18. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines
19. Human 60-kDa heat-shock protein: A danger signal to the innate immune system
20. Vascular smooth muscle-derived relaxing factor (MDRF) and its close similarity to nitric oxide
21. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood
22. Effects of cholera toxin on macrophage production of co-stimulatory cytokines
23. Microbial cell-wall contaminants in peptides: A potential source of physiological artifacts
24. Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant
25. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor β1 and β2 chain expression
26. Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages
27. Adaptation to bacterial lipopolysaccharide controls lipopolysaccharide- induced tumor necrosis factor production in rabbit macrophages
28. Molecular mechanism in tolerance to lipopolysaccharide
29. Lipopolysaccharide induces hyporesponsiveness to its own action in RAW 264.7 cells
30. Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis
31. Interleukin-10 is upregulated in LPS tolerance
32. Mechanism of endotoxin desensitization: Involvement of interleukin 10 and transforming growth factor B
33. Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation
34. Mechanisms of oral tolerance
35. Lipopolysaccharide-induced selective priming effects on tumor necrosis factor α and nitric oxide production in mouse peritoneal macrophages
36. Dissociation of lipopolysaccharide (LPS)-inducible gene expression in murine macrophages pretreated with smooth LPS versus monophosphoryl lipid A
37. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro
38. Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant function in vivo
39. Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract
40. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin
41. Cholera toxin-induced tolerance to allografts in mice
42. Cholera toxin induced tolerance to murine allografts
43. The immunological consequences of feeding cholera toxin. II. Mechanisms responsible for the induction of oral tolerance for DTH
44. Modulation of experimental autoimmune neuritis in Lewis rats by oral application of myelin antigens